Research on Cellular Immune Targeted Drug Therapy for Breast Cancer based on Bioinformatics

Targeted therapy, because of its precise location, high efficiency and low toxicity, has become an important tumor treatment method besides traditional treatments such as surgery, radiotherapy and chemotherapy. Targeted drugs can deliver therapeutic drugs to target organs to the maximum extent, but have little effect on non-target organs, thus achieving high-efficiency and low-toxicity therapeutic effects, especially for treating diseases such as cancer. At the cellular and molecular level, molecular targeting means that drugs enter the body and specifically bind with carcinogenic sites on tumor cells, resulting in the death of tumor cells, but it does not affect the surrounding normal tissues and cells. Studying the pathogenesis and related genes of breast cancer plays an active role in the early diagnosis and treatment of breast cancer, and effectively relieves the current status of clinical breast cancer treatment. In-depth study on molecular typing of breast cancer can provide further reference for the selection of clinical treatment schemes more effectively. This paper discusses the cellular immune targeted drug therapy for breast cancer from the perspective of bioinformatics.